Post-earnings recap
Reported
Mon, Aug 4, 2025
EPS actual
$-2.40
EPS est.
$-1.41
EPS surprise
-70.58%
1-day move
+6.24%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that CRISPR Therapeutics is facing significant challenges, particularly reflected in their EPS miss. Despite this, the stock rose by 6.24%, likely driven by investor optimism about future developments in their research pipeline. The lack of revenue data and guidance adds uncertainty, but the stock's positive reaction suggests some investors are hopeful about the company's long-term potential.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.40 | N/A | -70.58% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current operational hurdles but remains committed to their long-term strategy. They highlighted the importance of innovation in their research efforts.
Management acknowledged the challenges faced in the quarter.
They emphasized ongoing efforts to advance their pipeline despite setbacks.